Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy Trial in NASH
Shots:
- Gilead collaborates with Novo for the onset of a clinical trial combining its Firsocostat and Cilofexor with Novo’s Semaglutide for the treatment of patients with Nonalcoholic Steatohepatitis (NASH)
- The focus of the collaboration is to combine Gilead and Novo’s expertise for the enhancement of research capabilities and approaches developing novel therapies in NASH
- Semaglutide is a long-acting GLP-1 analogue administered qd to treat non-alcoholic fatty liver disease (NASH). Cilofexor and Firsocostat is a FXR agonist and ACC inhibitor respectively evaluated in P-II targeted for NASH
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com